These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18524994)

  • 21. The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells.
    Steiro I; Vandsemb EN; Elsaadi S; Misund K; Sponaas AM; Børset M; Abdollahi P; Slørdahl TS
    Oncotarget; 2022 Oct; 13():1175-1186. PubMed ID: 36268559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
    Cao Y; Shan H; Liu M; Liu J; Zhang Z; Xu X; Liu Y; Xu H; Lei H; Yu M; Zhang X; Liu W; Bu Z; Fang Z; Ji Y; Yan H; Gu W; Wu Y
    Cell Death Dis; 2021 Apr; 12(4):396. PubMed ID: 33854043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoparticles Dual Targeting Both Myeloma Cells and Cancer-Associated Fibroblasts Simultaneously to Improve Multiple Myeloma Treatment.
    Wang H; Liu H; Sun C; Liu C; Jiang T; Yin Y; Xu A; Pang Z; Zhang B; Hu Y
    Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33670464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
    Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
    Clin Exp Med; 2020 Feb; 20(1):63-71. PubMed ID: 31650359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
    D'Oronzo S; Coleman R; Brown J; Silvestris F
    J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus.
    Qu C; Zhang J; Zhang X; Du J; Su B; Li H
    Exp Ther Med; 2019 Feb; 17(2):1390-1394. PubMed ID: 30680018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
    Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
    Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Insights in Anti-Angiogenesis in Multiple Myeloma.
    Ribatti D; Vacca A
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
    Manni S; Carrino M; Semenzato G; Piazza F
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting tumour microenvironment by tyrosine kinase inhibitor.
    Tan HY; Wang N; Lam W; Guo W; Feng Y; Cheng YC
    Mol Cancer; 2018 Feb; 17(1):43. PubMed ID: 29455663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.
    Gao Q; Yellapantula V; Fenelus M; Pichardo J; Wang L; Landgren O; Dogan A; Roshal M
    Mod Pathol; 2018 Jun; 31(6):881-889. PubMed ID: 29403080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
    Seo S; Suh W
    Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.
    Bosseboeuf A; Allain-Maillet S; Mennesson N; Tallet A; Rossi C; Garderet L; Caillot D; Moreau P; Piver E; Girodon F; Perreault H; Brouard S; Nicot A; Bigot-Corbel E; Hermouet S; Harb J
    Front Immunol; 2017; 8():1347. PubMed ID: 29098000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Logic programming reveals alteration of key transcription factors in multiple myeloma.
    Miannay B; Minvielle S; Roux O; Drouin P; Avet-Loiseau H; Guérin-Charbonnel C; Gouraud W; Attal M; Facon T; Munshi NC; Moreau P; Campion L; Magrangeas F; Guziolowski C
    Sci Rep; 2017 Aug; 7(1):9257. PubMed ID: 28835615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma.
    Ribatti D
    Pharmaceuticals (Basel); 2010 Apr; 3(4):1225-1231. PubMed ID: 27713297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.
    Raica M; Cimpean AM
    Pharmaceuticals (Basel); 2010 Mar; 3(3):572-599. PubMed ID: 27713269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinase inhibitors as potential agents in the treatment of multiple myeloma.
    Abramson HN
    Oncotarget; 2016 Dec; 7(49):81926-81968. PubMed ID: 27655636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
    Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
    Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
    de la Puente P; Azab F; Muz B; Luderer M; Arbiser J; Azab AK
    Leuk Lymphoma; 2016 Jul; 57(7):1677-86. PubMed ID: 26421357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
    Păunescu E; Clavel CM; Nowak-Sliwinska P; Griffioen AW; Dyson PJ
    ACS Med Chem Lett; 2015 Mar; 6(3):313-7. PubMed ID: 25815152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.